Wednesday, July 1, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

‘Stealth’ omicron cases rising in the US: Here’s what we know

The omicron subvariant BA.2, also known as “stealth” omicron, has steadily grown more common in the U.S. since it was first detected in the country in January, but that doesn’t mean it will trigger a huge new wave of infection. That said, some experts are still concerned that such a surge could occur.

Here’s what you should know about the rise of stealth omicron in the U.S.:

Scientists first identified the subvariant back in December 2021, Live Science previously reported. At that time, they discovered that the original omicron lineage had split in two. They designated the original version of the variant as BA.1 and its genetically distinct spin-off as BA.2.

Source: Live Science

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!